Cat.nr.L3800
Een unieke collectie van 4200 geneesmiddelen die wereldwijd op de markt zijn gebracht of klinische fase 1 hebben doorlopen en kunnen worden gebruikt voor high-throughput screening (HTS) en high-content screening (HCS).
Geciteerd door 335 Publicaties
• A unique collection of 4200 drugs that are marketed around the world or have passed clinical phase 1 and can be used for high throughput screening (HTS) and high content screening (HCS)
•Drug repurposing, the application of known drugs to treat new disease indication, holds potential of rapid clinical impact at a lower cost than de novo drug development
• Safety confirmed by clinical phase 1
• Related to oncology, cardiology, anti-inflammatory, immunology, neuropsychiatry, analgesia etc
• Structurally diverse, medicinally active, and cell permeable.
• Rich documentation with structure, IC50, and customer reviews
• NMR and HPLC validated to ensure the highest purity
| Formulering | 3768 compounds pre-dissolved in 10mM DMSO, 301 compounds pre-dissolved in 10mM water, 110 compounds pre-dissolved in 2mM DMSO, 19 compounds pre-dissolved in 2mM water and 2 compounds pre-dissolved in 2mg/ml DMSO | ||
|---|---|---|---|
| Container | 96 Deep Well Plaat verzegeld met aluminiumfolie | ||
| Stabiliteit | 12 months | -20°C | in DMSO |
| 24 months | -80°C | in DMSO | |
| Verzending | Koude elementen of droogijs | ||
Toepassing van GPCR Compound Library bij leverkanker (Dit artikel is gepubliceerd in Nature (IF
Toepassing van Kinase Inhibitor Library bij darmkanker (Dit artikel is gepubliceerd in Nature Communications (IF
Toepassing van FDA-approved Drug Library bij antivirus (Dit artikel is gepubliceerd in Cell Research (IF
Toepassing van FDA-approved Drug Library in metabolisme (Dit artikel is gepubliceerd in Movement Disorders (IF
Toepassing van Epigenetics Compound Library bij acute lymfatische leukemie (Dit artikel is gepubliceerd in Blood (IF
Toepassing van Inhibitor Library in tumorimmunologie (Dit artikel is gepubliceerd in Cancer Immunol Res (IF